Roche has launched an updated version of its cobas 6800/8800 systems and software in the U.S. These updates were approved by the FDA earlier this year and are designed to improve laboratory efficiency and testing.
Key features of the update include:
- Increased test capacity: Labs can now run up to six tests at a time (up from three) and process more tests per sample. This speeds up testing and helps labs handle higher volumes.
- Dual testing options: The new system allows labs to run both Laboratory Developed Tests (LDT) and In-Vitro Diagnostic (IVD) tests together, making lab work easier and more flexible.
- Boosted performance: With a second analytic unit on the cobas 6800 system, labs can handle up to 2,112 tests per day. This helps meet growing demand and allows labs to adapt quickly to changes without losing productivity.
The cobas 6800/8800 systems are built for mid- to high-volume molecular testing labs, providing a smoother user experience and better efficiency.
Roche, founded in 1896 in Switzerland, is one of the world’s largest biotechnology companies and a leader in in-vitro diagnostics. The company is focused on improving healthcare through advanced diagnostics and medicines.
Executive Statement
According to Brad Moore, President and CEO, Roche Diagnostics North America, this update is significant because it not only allows for new innovation in PCR-testing technology and more choices in omni-channel testing, but it also addresses some key improvements that customers have told us are high priorities for them. All of these updates and improvements can be made to existing 6800/8800 systems through the software upgrade, providing higher throughput to laboratories with the same footprint and delivering more flexibility to physicians and patients.